Zusammenfassung
Die Zahl alter Menschen und damit die Zahl alter Patienten mit Krebserkrankungen wird weiter zunehmen. Das mittlere Erkrankungsalter beträgt derzeit ca. 70 Jahre. Mit zunehmendem Alter nimmt aber nicht nur die Zahl der Krebserkrankungen zu, auch die Inzidenz und die Prävalenz nicht-maligner Erkrankungen steigen. Ein wesentlicher Aspekt, der alte von jungen Patienten mit Krebserkrankungen unterscheiden kann, ist daher das Vorliegen von Komorbiditäten bzw. das Bestehen einer Multimorbidität. Diese führt häufig zur Polypharmazie. Der nachfolgende Beitrag geht auf den Stellenwert von Komorbiditäten/Multimorbidität im Rahmen der Betreuung alter Patienten mit Krebserkrankungen ein. Er definiert Ko- bzw. Multimorbidität, beschreibt mögliche gemeinsame Ursachen von Ko- bzw. Multimorbidität und Krebserkrankungen, berichtet Daten zur Prävalenz, stellt Methoden der strukturierten Erfassung dar und bewertet die prognostische Relevanz und den Stellenwert im Rahmen von Therapieentscheidungen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Albertsen PC et al (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156(1):127–132
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW (2005) Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294(6):716–724
Caillet P et al (2014) Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. Clin Interv Aging 9:1645–1660
Castro MA, Dedivitis RA, Ribeiro KC (2007) Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 69(3):146–152
Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
Charlson M et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251
Coebergh JW et al (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136
Cristofanilli M et al (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122–1128
Edwards BK et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120(9):1290–1314
Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4):453–471
Extermann M et al (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4):1582–1587
Fleming ST et al (1999) A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 37(6):601–614
Giles FJ et al (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624–627
Given B et al (2001) Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 50(4):222–232
Goede V et al (2016) Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma 57(4):789–796
Greenfield S et al (1987) Patterns of care related to age of breast cancer patients. JAMA 257(20):2766–2770
Greenfield S et al (1995) Development and testing of a new measure of case mix for use in office practice. Med Care 33(4 Suppl):AS47–AS55
Hershman DL et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 34(25):3014–3022
Hurria A et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465
Janssen-Heijnen ML et al (2005) Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res 124:89–107
Jorgensen TL et al (2012) Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer 106(7):1353–1360
Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7–8):387–404
Linn E S et al (1968) Cumulative illness rating scale. journal of American Geriarrics Society 16:622–626.
Mandelblatt JS et al (2001) Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 36(6 Pt 1):1085–1107
Newschaffer CJ et al (1998) Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci 53(5):M372–M378
Salvi F et al (2008) A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56(10):1926–1931
Sarfati D (2012) Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 65(9):924–933
Sarfati D et al (2016) Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival. Asia Pac J Clin Oncol 12(1):e47–e56
Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120(2):104–110
Sogaard M et al (2013) The impact of comorbidity on cancer survival: a review. Clin Epidemiol 5(Suppl 1):3–29
Sorror ML et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919
St Germain D et al (2014) Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract 10(2):e73–e80
Stier DM et al (1999) Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 54(3):424–429
Valderas JM et al (2009) Defining comorbidity: implications for understanding health and health services. Ann Fam Med 7(4):357–363
Wedding U, Höffken K (2002) Komorbiditäten. In: Höffken K, Kolb G, Wedding U (Hrsg) Geriatrische Onkologie. Springer, Heidelberg
Wedding U, Pientka L, Hoffken K (2007a) Quality-of-life in elderly patients with cancer: a short review. Eur J Cancer 43(15):2203–2210
Wedding U et al (2007b) Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 61(3):269–276
Welch HG et al (1996) Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 124(6):577–584
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Wedding, U., Schäffer, T. (2018). Komorbidität unter geriatrischen Aspekten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48727-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-48727-3_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48726-6
Online ISBN: 978-3-662-48727-3
eBook Packages: Medicine (German Language)